To characterize micromegaly and compare it with acromegaly in terms of clinical features, comorbidities, and treatment response based on hormonal data.
Approach:
Patient Enrollment: 30 patients with micromegaly and 30 matched patients with acromegaly were enrolled, focusing on hormonal data and comorbidities.
Data Collection: Clinical and hormonal data were retrospectively collected, including IGF-1 levels and GH nadir after glucose load.
Laboratory Analysis: Pituitary tissue samples were analyzed for GH isoform expression and proliferative rate.
Key Findings:
Patients with acromegaly exhibited significantly higher IGF-1 values at diagnosis (+8.3 vs. +3.2 SDS, p < 0.01) and higher GH nadir levels after glucose load (6 vs. 0.15 μg/L, p < 0.01).
52% of micromegaly patients showed no evidence of pituitary adenoma.
The prevalence of most comorbidities was similar between both groups, except for valve disease (42.9% vs. 16.7%, p = 0.006) and diabetes (56.7% vs. 23.3%, p = 0.016), which were more common in acromegaly.
Interpretation:
Micromegaly presents a unique clinical profile with a high burden of comorbidities.
Limitations:
The study is retrospective and conducted at a single center, limiting generalizability.
The sample size is small, which may affect the robustness of the findings.
Conclusion:
Micromegaly requires appropriate screening and follow-up due to its comorbidities.
In a pooled analysis of two randomized crossover trials, reducing nightly sleep by about 1.5 hours for 6 weeks was associated with modest increases in body weight and waist circumference without measurable changes in body composition.
